1. A preparation containing a therapeutically effective amount of an antibody in histidine-arginine buffer, pH 4.5 to 6.5.2. The preparation according to claim 1, wherein the buffer is a buffer based on histidine acetate-arginine acetate, a pH from 5.0 to 6.0, or in which the buffer is a buffer based on histidine succinate arginine, a pH from 5.0 to 6 , 0.3. The drug according to claim 2, in which the concentration of histidine acetate or histidine succinate in the buffer is from about 5 mm to about 100 mm. The drug according to claim 2, in which the concentration of histidine acetate or histidine succinate is about 20 mm. The drug according to claim 2, in which the concentration of arginine acetate or arginine succinate in the buffer is from about 50 mm to about 500 mm. The preparation according to claim 2, wherein the concentration of arginine acetate or arginine succinate is about 150 mM. The drug according to claim 1, additionally containing a surfactant. The drug according to claim 7, in which the surfactant is polysorbate. The preparation of claim 8, wherein the polysorbate is polysorbate 20.10. The preparation according to claim 9, wherein the concentration of the surfactant is from 0.0001% to about 1.0%. The preparation of claim 10, wherein the concentration of the surfactant is from about 0.01% to about 0.1%. The preparation according to claim 11, wherein the concentration of the surfactant is 0.02%. The preparation according to claim 1, wherein the antibody concentration is from about 10 mg / ml to about 250 mg / ml； from about 100 mg / ml to 250 mg / ml； from about 150 mg / ml to about 200 mg / ml； or from about 25 mg / ml to about 200 mg / ml. 14. The drug according to claim 1, where the antibody is not subjected to preliminary lyophilization. The drug1. Препарат, содержащий терапевтически эффективное количество антитела в гистидиновом-аргининовом буфере, рН от 4,5 до 6,5.2. Препарат по п.1, в котором буфером является буфер на основе ацетата гистидина-ац
